Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
5.7
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2024年4月1日〜2024年6月30日ConsolidatedIFRSNet Sales39,131Millions of yenYear on year +5.7%Progress 25.4%
Operating profit11,078Millions of yenYear on year -0.8%Progress 34.6%
Ordinary income11,411Millions of yenYear on year -0.3%Progress 35.1%
Net income attributable to owners of the parent10,264Millions of yenYear on year +17.3%Progress 35.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share152.40円
Financial position at period-end
Total assets265,828Millions of yen
of which net assets 227,462 Millions of yenEquity ratio 85.4%vs. prior year-end +1.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+7,004
Investment-6,788
Financials-4,328
Net change-4,112
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period54,472 Millions of yen
Segment revenue
Pharmaceuticals Business33,73886.2%+9.3%
Functional Foods Business5,39313.8%-12.2%
Segment profit
Pharmaceuticals Business10,03695.4%
Functional Foods Business4794.6%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales154,000 Millions of yen (YoY +3.9%)
Operating profit32,000 Millions of yen (YoY -3.9%)
Ordinary income32,500 Millions of yen (YoY -3.3%)
Net income29,000 Millions of yen (YoY +12.2%)
Revision to Earnings ForecastNet Sales Not disclosed → 154,000 Millions of yen / Operating profit Not disclosed → 32,000 Millions of yen / Ordinary income Not disclosed → 32,500 Millions of yen / Net income Not disclosed → 29,000 Millions of yen
Annual Dividend Forecast¥124 → ¥124（0.0%）
Factors Behind Changes in Business Performance
売上収益は医薬品事業でウプトラビ、海外売上に伴うロイヤリティ収入、ビルテプソ等が伸長したため増収。機能食品事業はプロテイン製剤等の売上減少により減収。営業利益は販売費及び一般管理費や研究開発費の増加により減益。親会社の所有者に帰属する四半期利益は法人所得税費用の減少等により増益。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies (company name: —) / Excluded 0 companies (company name: —)
Depreciation and amortization1,464 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Conference call for institutional investors and securities analysts
Issued Shares at Period-End70,251,484
Treasury Shares at Period-End2,898,786
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年6月30日 |
| Net Sales | 39,131 Millions of yen (YoY +5.7%) |
| Operating profit | 11,078 Millions of yen (YoY -0.8%) |
| Ordinary income | 11,411 Millions of yen (YoY -0.3%) |
| Profit attributable to owners of the parent | 10,264 Millions of yen (YoY +17.3%) |
| Net income per share | 152.40円 |
| Equity ratio | End of the current fiscal period 85.4 / End of previous period 83.6 |
| Total assets | 265,828 Millions of yen |
| Net assets | 227,462 Millions of yen |
| Cash flows from operating activities | 7,004 Millions of yen |
| Cash flows from investing activities | -6,788 Millions of yen |
| Cash flows from financing activities | -4,328 Millions of yen |
| Cash and cash equivalents at end of period | 54,472 Millions of yen |
| Full-year earnings forecast | Net Sales 154,000 Millions of yen (YoY +3.9%) / Operating profit 32,000 Millions of yen (YoY -3.9%) / Ordinary income 32,500 Millions of yen (YoY -3.3%) / Net income 29,000 Millions of yen (YoY +12.2%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → 154,000 Millions of yen / Operating profit Not disclosed → 32,000 Millions of yen / Ordinary income Not disclosed → 32,500 Millions of yen / Net income Not disclosed → 29,000 Millions of yen |
| Annual Dividend Forecast | ¥124 → ¥124（0.0%） |
| Segment revenue | Pharmaceuticals Business 33,738 Millions of yen (YoY +9.3%) / Functional Foods Business 5,393 Millions of yen (YoY -12.2%) |
| Segment profit | Pharmaceuticals Business 10,036 Millions of yen / Functional Foods Business 479 Millions of yen |
| Depreciation and amortization | 1,464 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Conference call for institutional investors and securities analysts |
| Issued Shares at Period-End | 70,251,484 |
| Treasury Shares at Period-End | 2,898,786 |
| Factors Behind Changes in Business Performance | 売上収益は医薬品事業でウプトラビ、海外売上に伴うロイヤリティ収入、ビルテプソ等が伸長したため増収。機能食品事業はプロテイン製剤等の売上減少により減収。営業利益は販売費及び一般管理費や研究開発費の増加により減益。親会社の所有者に帰属する四半期利益は法人所得税費用の減少等により増益。 |
Items this document does not state (8)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上収益は、医薬品事業で「ウプトラビ」、海外売上に伴うロイヤリティ収入、「ビルテプソ」等が伸長したため増加しました。営業利益は販売費及び一般管理費や研究開発費の増加により減少し、親会社の所有者に帰属する四半期利益は法人所得税費用の減少等により増加しました。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.